Recent data indicate that TGFβ, either through acting as a surface-bound ligand on Tregs or via increasing the CD4+Treg/CD4+Th ratio, impairs the anti-tumor response in melanoma and other skin cancers via regulatory T cells14,38. This evidence concerns the gene CD4 and melanoma.